ArticleCancer immunology, immunotherapy : CII2021

Polymorphism of formyl peptide receptor 1 (FPR1) reduces the therapeutic efficiency and antitumor immunity after neoadjuvant chemoradiotherapy (CCRT) treatment in locally advanced rectal cancer.

Shu-Fen Chiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.